-

CoreCard Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CoreCard Corporation - CCRD

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CoreCard Corporation (NYSE: CCRD) to Euronet Worldwide, Inc. (NasdaqGS: EEFT). Under the terms of the proposed transaction, each share of CoreCard common stock will be exchanged for a number of shares of Euronet common stock equal to an exchange ratio between 0.2783 and 0.3142, calculated as $30 divided by the volume weighted average share price of Euronet common stock over the 15-trading day period ending on and including the second to last trading day prior to the closing date (the “Final Euronet Stock Price”), subject to a floor of $95.48 per share and a ceiling of $107.80 per share. CoreCard shareholders will receive 0.3142 Euronet shares for each of their CoreCard shares if the Final Euronet Stock Price is at or below $95.48, and 0.2783 Euronet shares for each of their CoreCard shares if the Final Euronet Stock Price is at or above $107.80. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nyse-ccrd/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Contacts

Kahn Swick & Foti, LLC
Lewis S. Kahn, KSF Managing Partner
lewis.kahn@ksfcounsel.com
855-768-1857

Kahn Swick & Foti, LLC

NYSE:CCRD

Release Versions

Contacts

Kahn Swick & Foti, LLC
Lewis S. Kahn, KSF Managing Partner
lewis.kahn@ksfcounsel.com
855-768-1857

Social Media Profiles
More News From Kahn Swick & Foti, LLC

Celsius Holdings, Inc. Securities Fraud Class Action Result of Health and Marketing Misrepresentations and Over 7% Stock Decline - Investors May Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until November 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against Celsius Holdings, Inc. (“Celsius” or the “Company”) (NasdaqCM: CELH), if they purchased the Company’s securities between February 21, 2025 and June 3, 2026, inclusive (the “Class Period”...

Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc. - LNTH

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Lantheus Holdings, Inc. (NasdaqGM: LNTH) to Curium US Holdings LLC. Under the terms of the proposed transaction, shareholders of Lantheus will receive $102.50 per share in cash, plus non-transferable Contingent Value Rights providing for up to $12.00 per share in potential additional cash payments,...

BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioLife Solutions, Inc. (NasdaqCM: BLFS) to Repligen Corporation (NasdaqGS: RGEN). Under the terms of the proposed transaction, shareholders of BioLife will receive $11.25 in cash and 0.1442 shares of Repligen common stock for each share of BioLife that they own. KSF is seeking to determine whether t...
Back to Newsroom